Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $10.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target reduced by equities researchers at Stifel Nicolaus from $32.00 to $10.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 101.21% from the company’s current price.

A number of other analysts also recently issued reports on ZNTL. Wedbush downgraded Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $15.00 to $4.00 in a research report on Tuesday. HC Wainwright lowered their target price on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, Wells Fargo & Company lowered shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $18.86.

Zentalis Pharmaceuticals Stock Down 40.8 %

ZNTL traded down $3.42 during midday trading on Tuesday, hitting $4.97. 12,740,104 shares of the company were exchanged, compared to its average volume of 852,391. The firm’s 50 day moving average price is $11.77 and its 200-day moving average price is $13.13. Zentalis Pharmaceuticals has a 1-year low of $4.96 and a 1-year high of $30.53. The firm has a market capitalization of $353.02 million, a P/E ratio of -1.45 and a beta of 1.83.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to the consensus estimate of $35.00 million. During the same period in the prior year, the company earned ($1.07) earnings per share. On average, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the transaction, the chief financial officer now owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $38,000. Tower Research Capital LLC TRC grew its holdings in Zentalis Pharmaceuticals by 252.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after buying an additional 2,589 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after purchasing an additional 1,519 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Zentalis Pharmaceuticals by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after buying an additional 6,379 shares during the last quarter. Finally, OneAscent Financial Services LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $156,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.